Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a myeloproliferative disease. While tyrosine kinase inhibitors (TKI) that target
the kinase activity of BCR-ABL1 have transformed CML from a once fatal disease to a manageable one for the vast majority of patients, only ~10% of those who present in chronic phase (CP) can discontinue TKI treatment and maintain a therapy-free remission. Strong evidence now shows that CML LSC are resistant to the effects of TKIs and they persist in all patients on long-term therapy, where they may promote acquired TKI resistance, drive relapse or disease progression and inevitably represent a bottleneck to cure. Since their discovery in patients almost two decades ago, CML LSC have become a well-recognised exemplar of the cancer stem cell and have been characterised extensively with the aim of developing new curative therapeutic approaches based on LSC eradication. This review summarises our current understanding of many of the pathways and mechanisms that promote the survival of the CP CML LSC and how they can be a source of new gene coding mutations that impact in the clinic. We also review recent pre-clinical approaches that show promise to eradicate the LSC, and future challenges on the path to cure.
CML: THE CLASSIC STEM CELL DISEASE
Chronic myeloid leukaemia (CML) is a classic example of a stem cell cancer and arises when the t9;22 translocation (the Philadelphia chromosome) [1] [2] [3] occurs in a haemopoietic stem cell (HSC). This event results in the constitutive expression of the fusion tyrosine kinase BCR-ABL1, transforming the HSC into the CML stem cell (referred to here as the leukaemic stem cell or LSC) which then gives rise to a clonal myeloproliferative disease. Early evidence regarding the HSC origins of CML came from observations that transfusion of peripheral blood cells from CML patients into severely neutropenic recipients resulted in temporary homologous BM engraftment and Ph + progeny in the blood 4 . This was later explained by the presence of high numbers of mobilised LSC in the peripheral blood of chronic phase (CP) CML patients 5 . A possible haemopoietic progenitor origin of CML was ruled out when BCR-ABL1 expression in murine haemopoietic progenitors failed to confer self-renewal capabilities to BCR-ABL1 + cells, and these cells failed to induce leukaemia in mice 6 . Until very recently, BCR-ABL1 expression was considered sufficient to cause a CML-like disease in mouse models using retrovirus transduction or transgene insertional mutagenesis to express the oncogene in LSC [7] [8] [9] . However, issues with BCR-ABL1 copy number, high oncogene expression and/or secondary mutations arising by retroviral or transgene insertional mutagenesis or genomic instability could theoretically contribute to leukaemogenesis. In a recent knock-in model, a single copy of BCR-ABL1 expressed from the endogenous BCR locus was able to confer enhanced BM engraftment, however this model was unable to induce leukaemia 10 .
Whilst the cell of origin of CML is generally accepted to be the HSC, several studies implicate an HSC-precursor cell -the multipotent haemangioblast that gives rise to both haemopoietic and endothelial cells. The BCR-ABL1 fusion can be detected in endothelial cells obtained from BM and peripheral blood of CML patients at varying frequencies 11, 12 . These cells show altered intra-cellular signalling and protein expression that may affect crosstalk between LSC and the bone marrow microenvironment (BMM), alter immune-modulation and LSC exit from quiescence into proliferation 13, 14 . Collectively these data suggest that the acquisition of BCR-ABL1 in the haemangioblast may contribute to both malignant haemopoiesis and endotheliopoiesis.
THE NATURAL HISTORY OF CML
CML is a rare stem cell disease with an annual incidence of 1-2 cases per 100,000 individuals peaking in the sixth and seventh decades of life 15 . Data derived from atomic bomb survivors 16 suggest that following a latent period of some 7 years, the natural history of CML is for 85-90% of cases to present in CP, but to progress to accelerated phase (AP) and then to either myeloid or lymphoid blast crisis (BC) over a 5 year time frame 17 . However, the mechanism of disease progression is complex and disease behaviour is highly variable for individual patients, with some progressing within a few months and others remaining in stable CP for up to 20 years. This heterogeneity between patients may relate to the mutations subsequently acquired in the BCR-ABL1 clone 18 , variations in gene expression patterns between patients 19 , or the subtype of HSC in which BCR-ABL1 is first expressed -with recent evidence delineating multiple HSC subsets defined by variably fixed lineage potentialities, transcriptional profiles and phenotypes [20] [21] [22] [23] .
Furthermore, intriguing work on pre-leukaemia 24,25 and the detection of BCR-ABL1 in blood cells of normal individuals 26,27 presents the possibility that heterogeneity could also be driven by mutations acquired before or after BCR-ABL1, or other factors such as deregulation and skewing of lineage specification, clonal haemopoiesis, DNA damage, activation of inflammatory responses, and epigenetic alterations, all of which occur in haemopoiesis during aging 28, 29 . Some, or all, of these factors may also be required for, or contribute to, disease development in mouse models of CML.
LSC PERSISTENCE: A BOTTLENECK TO CURE
The introduction of a potent BCR-ABL1 tyrosine kinase inhibitor (TKI), imatinib, almost two decades ago, followed by subsequent generations of TKI (dasatinib, nilotinib, bosutinib, ponatinib) has transformed the management of CML 30, 31 . What was once a universally fatal disorder, unless treated with an allogeneic transplant, is now well controlled in the outpatient setting and overall survival has improved significantly (http://seer.cancer.gov/statfacts/html/cmyl.html) with the majority of patients requiring life-long TKI. In keeping with disease heterogeneity, patient responses to TKI are also variable. The majority of cases (50-70%) achieve major molecular response (MMR) where BCR-ABL1 levels detectable by quantitative PCR (qPCR) in the blood show a 3 log10 fold reduction, i.e., 0.1%, compared to a standardised baseline (reviewed elsewhere 32 ). However, patient to patient variation in leukaemic cell blood counts at diagnosis, and variations in BCR-ABL1 expression between early and late stages of cell differentiation can often confound these interpretations. Approximately 10-20% of all patients develop even deeper molecular responses triggering dose de-escalation and discontinuation/stopping trials (STIM, TWISTER, DADI), where 50% of patients relapse within 12 months 33,34 . When CP relapse occurs, the doubling time (≈ 9 days) for increasing disease burden mirrors the CML disease at diagnosis 35 . A quarter of CP patients fail TKI therapy 36 , and approximately half of these cases can be explained by BCR-ABL1 kinase domain mutations 32,37 but the reason for failure in the remaining patients is unclear.
Ironically, the earliest evidence of CML LSC 38 pre-dated the introduction of TKI and this was followed by definitive evidence of a deeply, but reversibly, quiescent subpopulation of leukaemic cells in patients with CML 39 . In the subsequent years, the consensus view has emerged that virtually all CP patients on TKI therapy and in MMR are not cured of CML and show signs of residual disease burden due to the presence of LSC in the BM (termed "LSC persistence"). In a typical cohort of 100 CP CML patients who undertake TKI therapy over a 5 year period, almost twothirds of them will have this "LSC persistence" phenotype ( Figure 1 ). Researchers have consistently detected BCR-ABL1 + primitive cells in the BM of TKI-treated patients in MMR which are capable of growth in colony forming cell (CFC) and longterm culture initiation cell (LTC-IC) assays, even in patients in deep molecular response with no detectable BCR-ABL1 transcripts by qPCR [40] [41] [42] [43] . The most recent of these studies have shown that although LSC are not always detectable in cases of very deep molecular response, most likely due to technical limitations, some patients with no detectable LSC can subsequently relapse after TKI discontinuation 43 . Others have shown that the LSC that persist in patients in MMR express BCR-ABL1 at lower levels than LSC at the point of diagnosis. Furthermore, murine BM cells engineered to express low levels of BCR-ABL1 levels were far less sensitive to imatinib, while those expressing higher levels were prone to de novo mutations 44 . These findings point to LSC persistence as a "low mutator" phenotype, perhaps explaining why the majority of these patients do not develop drug resistance or progress to BC. The eradication of the LSC remains a challenge in the majority of CML patients, a significant bottleneck to cure, and an area of intensive research.
GENERAL FEATURES OF THE LSC
At time of CP diagnosis, BCR-ABL1 -cells co-exist with BCR-ABL1 + cells and enriched CD34 + populations require dual-fluorescent in situ hybridisation (D-FISH) to determine the proportion of cells that carry the Ph + (usually >90% BCR-ABL1 + ).
The more primitive LSC fraction can be purified by fluorescence-activated cell sorting (FACS) in a variety of ways, giving rise to overlapping, primitive, quiescent populations ( Figure 2 ). Phenotypically and functionally, we define the CP CML LSC as those primitive stem/progenitor cells that show a higher capacity to engraft in immunocompromised mice than bulk CD34 + cells 45 , have stem cell properties (selfrenewal), are resistant to apoptosis 46, 47 , are prone to genomic instability 48, 49 and have impaired DNA damage responses [50] [51] [52] . Since BCR-ABL1 drives survival and proliferation, it is somewhat of a paradox that CML LSC express BCR-ABL1 but can also be quiescent 39 -a feature which may enable them to become refractory to TKIinduced apoptosis. However, TKI also exert a potent anti-proliferative effect on CML CD34 + cells and LSC to induce quiescence 46, 53 and subsequent evidence has shown that TKI exert additional effects to subvert a number of pathways to promote survival (see below).
BCR-ABL1 KINASE INDEPENDENT SURVIVAL
To understand why LSC were refractory to the effects of TKI, we exposed CML CD34 + cells to high concentrations of dasatinib for 12 days, and subjected them, in parallel, to BCR-ABL1 knockdown. These in vitro studies were complemented in vivo using the inducible transgenic SCL-tTA/BCR-ABL model 9 . BCR-ABL1 This work demonstrated that LSC survival is not dependent on BCR-ABL1 kinase activity 54 and suggested that BCR-ABL1 may have non-kinase mediated functions that modulate signalling pathways to promote LSC survival. These conclusions were further supported by others who used imatinib to fully inhibit BCR-ABL1 kinase activity in both LSC and quiescent cells 55 (kinase independent) and blocking this pathway reversed the effects of FOXO nuclear translocation 58, 59 . However, the precise mechanism of how this occurs is not fully understood and may not to be completely cell-autonomous.
HEDGEHOG SIGNALLING
Several studies have implicated the hedgehog pathway in the maintenance (selfrenewal) and proliferation of the LSC [60] [61] [62] , where Smoothened (SMO) is a critical mediator. Hedgehog binding to Patched (PTCH) activates SMO which in turn activates the transcription factor GLI1. This leads to reductions of NUMB expression and increased MDM2-mediated degradation of the p53 protein ( Figure   2 ). This would have the effect of suppressing apoptotic responses and/or cell cycle arrest through repression of p53 targets. SMO deletion or pharmacological inhibition in mouse models of CML blocked this pathway and led to loss of LSC 60, 61 .
However, TKI treatment alone was unable to block this pathway, suggesting that hedgehog signalling was kinase independent. More recently, similar results were obtained using SMO inhibitors in human CML samples in vitro and in vivo using xenografts in immunocompromised NOD scid gamma (NSG) mice 62 .
CANONICAL AND NON-CANONICAL WNT SIGNALLING
β-catenin is a central mediator of both canonical and non-Wnt signalling and has a dual role in regulating cell-to-cell contact through tight junctions and acting as a transcriptional regulator when translocated to the nucleus (Figure 2 ). In the absence of Wnt signalling, cytoplasmic β-catenin is ultimately phosphorylated by GSK3β and targeted for degradation by an axin-mediated multimeric complex. Nuclear β-catenin is required for self-renewal and survival of normal HSC 63 , and it therefore not surprising that it has also been shown to be a key mediator of LSC survival.
Loss of β-catenin in a murine model of CML impaired the development of the disease by inhibiting LSC self-renewal 64 , and genetic and pharmacological inhibition of β-catenin activity synergised with TKI to target the loss of LSC 65 and this involves its phosphorylation and translocation to the nucleus where it regulates transcription. Subsequent evidence has also shown that a single null mutation in the STAT5a isoform can attenuate CML-like disease in mouse models 71 and knockdown can impair Ph + myeloid colony formation from CML patient samples 72 . Modulating JAK2 activity in human and mouse cell lines reduces BCR-ABL1 and STAT5 signalling 73 , and pharmacological inhibition using ruxolitinib resulted in the loss of LSC both in vitro and in vivo 74 
GENOMIC INSTABILITY, DNA DAMAGE AND REPAIR
Whether TKI-induced quiescence contributes to LSC persistence in patients is still an open question. Two possible beneficial consequences of TKI treatment would be to reduce the turnover and expansion of LSC in patients and enhance a "low mutator" phenotype 44 . However, a more cautionary interpretation of these possible benefits has come from the examination of the mechanisms and pathways that contribute to genomic instability in LSC. BCR-ABL1 kinase activity leads to increased levels of reactive oxygen species (ROS) 48, 49, 81 , including H2O2, and these lead to oxidative DNA damage, including point mutations and double stranded breaks (DSB). In this regard, the RAC2 GTPase has been shown to alter the function of the mitochondrial respiratory chain complex (MRC-cIII) to generate ROS and DNA damage in LSC, as evidenced by the accumulation of chromosomal aberrations and clinically-relevant BRC-ABL1 kinase domain mutations 49 . This effect was also observed under hypoxia, the conditions that LSC are exposed to in the BM microenvironment, and during exposure to TKI where RAC2 levels were unaffected, thus demonstrating a kinase independent pathway. Inhibition of RAC2 or disruption of the MRC-cIII reduced the level of genomic instability. Similarly, high ROS levels and associated genomic damage were re-capitulated using the transgenic SCL-tTA/BCR-ABL model 48 where both BCR-ABL1 kinase domain mutations and various base pair additions/deletions in genes linked to progression to BC were identified in LSC in both TKI-naïve and TKI-treated mice. Evidence as to why such DNA damage is tolerated in LSC has also emerged. BCR-ABL1 can inhibit mismatch repair to protect cells from apoptosis 50 , and can stimulate singlestrand annealing, homologous recombination repair (HRR) and non-homologous end-joining, all of which are error-prone in BCR-ABL1 expressing cells 52, 81 .
Furthermore, LSC are dependent on the alternative RAD52-RAD51 pathway of HRR to deal with DSB rather than BRCA1/2-RAD51, due to the kinase independent down-regulation of BRCA1 82 . While we are unable to reconcile these data with a "low-mutator" phenotype 44 , they point to the LSC as a potent source of clinically relevant mutations, and also argue that CML is constantly evolving at the molecular level even in CP, countering the clinical view that it is a disease of 3 distinct phases.
THE LSC BONE MARROW MICROENVIRONMENT
While the pathways described above have ostensibly been studied as primarily cellintrinsic or cell-autonomous, it is likely that some, if not all, of them are regulated through interactions between the CML LSC and the BMM -and a number of these interactions have been identified (Figure 3 , Table 2 ), some of which mediate TKI resistance.
LSC adhesion within the BMM is likely to contribute to homing and lodgementcritical steps in LSC engraftment subsequent to transplantation. CD44, expressed on LSC, are ligands for e-selectins and lack of CD44 reduced homing and engraftment of LSC 83 . Similarly, a critical role for selectins and their ligands in engraftment has also been shown 84 and e-selectins can be blocked pharmacologically to reduce the number of LSC. The lectin GAL-3 mediates resistance to TKI through binding β-galactosides on stromal cells and overexpression activated AKT signalling and increased lodgement of LSC in the BM 85 .
β1-integrins mediate adhesion of LSC to BM stromal cells, a process likely to be regulated by interferon α 86, 87 . TKI-induced up-regulation of N-cadherin in LSC, and adhesion to mesenchymal stem cells led to increased canonical Wnt signalling and protection of the LSC from apoptosis 88 . The CXCL12 ligand and its receptor CXCR4 has been linked to intracellular LYN signalling in LSC 89 , and the CXCL12/CXCR4 axis is regulated through CXCL12 cleavage by CD26 90 . Reduced homing capacity of LSC has also been attributed to alterations of the CXCL12/CXCR4 signalling pathway as a result of increased granulocyte-colony stimulating factor (G-CSF) levels which conferred a selective growth disadvantage to normal HSC 91 . LSC also exert other molecular and phenotypic effects on HSC through extrinsic IL-6 signalling in the CML BMM 92, 93 . Indeed, a variety of ligand-receptor mediated signalling pathways regulate CML LSC in the BMM (Figure 3 , Table 2 ).
It is likely that LSC also avoid eradication by modulation of host immune surveillance in the BMM (reviewed in detail elsewhere 94 ). In this respect, cytotoxic T lymphocytes (CTLs) are unable to elicit an appropriate immune response against CML cells through CTL exhaustion -and this is believed to be mediated by the interaction of the PD-1 receptor expressed on CTLs with its inhibitory ligand PD-L1 expressed on CML cells. PD-L1 is expressed on patient derived CML cells 95 and on LSC in mouse models of CML 96 . Blockade of the PD-1/PD-L1 interaction in combination with T-cell immunotherapy was able to trigger the loss of LSC, and prevent development of CML-like disease 96 . Our recent work has demonstrated that cytokine-mediated downregulation of MHC-II expression may be an alternative way that LSC evade immune surveillance -and treatment with ruxolitinib or interferon gamma (IFNγ) can reverse this effect in vitro and enhance proliferation of responder CD4 + CD69 + T cells in mixed lymphocyte reactions 97 . These examples represent exciting areas of research that could lead to new immune therapy-based therapeutic approaches.
NEW THERAPIES TO TARGET LSC: RECENT APPROACHES
The many examples summarised above illustrate the scope of potentially drug-able targets that have been identified in CML to eradicate LSC (Tables 1-2 The TKI-mediated up-regulation of CD70 has been further examined to provide a clear rationale for inhibiting non-canonical Wnt/β-catenin signalling in LSC 67 . Upon exposure to TKI, the microRNA miR-29 is down-regulated -the consequence of which is up-regulation of CD70 through the opposing roles of miR-29 on SP1 and DNMT1a regulation ( Figure 4C ). Thus, antibody-based blockade of the interaction between CD70 and CD27 resulted in a potent loss of LSC in the presence of TKI 67 .
Two other routes for inhibiting β-catenin signalling in LSC have also recently been deduced. In the first, BCR-ABL1 interacts directly with JAK2 in a kinase independent manner to activate a JAK2/β-catenin survival/self-renewal pathway that results in inhibition of PP2A and activation of β-catenin ( Figure 4D ). Use of PP2A activating drugs (PADs) reversed these effects resulting in GSKβ-dependent degradation of β-catenin and eradication of LSC 77 . In the second, another enzyme in fatty acid metabolism arachidonate 15-lipoxygenase (15-LO encoded by ALOX15) has been implicated in the kinase independent up-regulation of β-catenin, although the exact mechanism is unclear. However, pharmacological inhibition of 15-LO in combination with nilotinib on human LSCs in vitro appeared synergistic 106 .
In addition, the p-selectin SELP appears to be a key down-stream target of 15-LO, which is normally repressed to promote LSC survival. Further pre-clinical studies and mechanistic studies are required to provide a clearer rationale for taking 15-LO inhibitors into clinical trials as has been done with zileuton which inhibits 5-LO 69 .
FUTURE CHALLENGES
We know little about how TKI-resistant LSC clones evolve in patients in MMR and the degree of intra-and inter-patient heterogeneity that is likely to exist -not only at the DNA level, but also with respect to the many pathways that we have identified by studying diagnostic drug-naïve LSC for many years. This is because (i) the TKI-resistant LSC are extremely rare in the BM of these CML patients, and (ii) the LSC cannot be selectively isolated from the normal HSC that reconstitute normal haemopoiesis in the BM subsequent to TKI therapy. Surrogate in vivo analysis has also been problematic since the majority of CML primary samples do not engraft well in commonly used immunodeficient mice strains. These issues most likely underpin the failure of many promising new drugs to deliver results in clinical trials. However, recent advances in tracking individual normal and malignant clones in xenograft models using bar-coding 21,107 , the development of humanised xenograft models 108 , an explosion of single cells technologies 20, 109 , and the identification of a number of leukaemia-specific cell surface markers, make the analysis of individual LSC or LSC clones much more accessible. Furthermore, several groups have identified markers that discriminate LSC from HSC (CD26 90 , IL-1RAP 110 , CD25 111 and CD93 112 ) but how these will perform in samples from patients in MMR has yet to be determined. For those of us that are intent on curing CML, this new era of game-changing technologies provides some tantalizing prospects that will enable us to finally stem the tide on drug-resistant LSC. Column four: references where the targets were described. Column five: whether targets or compounds have been evaluated in clinical trials. Outcomes were compiled based on data obtained from various sources 31, [143] [144] [145] [146] . By the end of year 5: twelve (12) (green segment of the pie chart) of these 100 patients will typically be off TKI and in therapy-free remission (TFR), more than a quarter (26) (red segment of the pie chart) will have failed TKI therapy (even after drug switching or through disease progression to AP or BC), and the majority (62) (amber segment of the pie chart) will remain on long-term TKI therapy but have residual disease due to LSC persistence in their BM. 
